Clinical stage biotech company Third Arc Bio Inc announced on Thursday that the first patient has been dosed in its first-in-human study assessing ARC101, a potential best-in-class T cell engager targeting Claudin 6 (CLDN6).
This Phase 1 study will evaluate the optimal dosing, safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor efficacy of ARC101 as monotherapy in patients with locally advanced or metastatic solid tumours expressing CLDN6.
ARC101 represents the company's first clinical effort to evaluate in humans its immune cell engaging antibodies that modulate the immune system in precise ways to target specific disease states.
Building on ARC101 as a foundation, Third Arc Bio continues to invest in its Synergy Platform to develop a pipeline of novel CD3 and CD28 targeting multispecifics to create advanced drugs against solid tumours.
Biophytis advances sarcopenia treatment with positive Phase 2 results
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer
BioSurfaces collaborates with Morphocell Technologies
iOncologi acquires TargImmune Therapeutics
Argent BioPharma announces positive CimetrA Phase IIb clinical trial results
Korro Bio receives FDA orphan drug designation for KRRO-110
SpliceBio doses first patient in Phase 1/2 ASTRA study of SB-007
Third Arc Bio reports first patient dosed in first-in-human study assessing ARC101
Amgen reports positive Phase 3 trial results for UPLIZNA in generalised myasthenia gravis
Celltrion launches STELARA biosimilar STEQEYMA in US market
Merck reports positive Phase 3 Data on HIV treatment DOR/ISL
Cantargia enrolls first patient in leukemia study with nadunolimab
Shilpa Medicare's Nor Ursodeoxycholic Acid Tablets IND receives regulatory approval in India